Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CYTH

Cyclo Therapeutics Inc

Apr 19 • 04:00PM ET

1.16

Dollar change -0.04
Percentage change -3.33	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	44.40%	Shs Outstand	28.56M	Perf Week	-7.94%
Market Cap	33.32M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.00%	Shs Float	15.96M	Perf Month	-18.88%
Income	-20.06M	PEG	-	EPS next Q	-0.17	Inst Own	7.71%	Short Float	0.29%	Perf Quarter	-28.40%
Sales	1.08M	P/S	30.85	EPS this Y	53.66%	Inst Trans	0.36%	Short Ratio	0.42	Perf Half Y	8.41%
Book/sh	0.17	P/B	6.96	EPS next Y	15.79%	ROA	-229.72%	Short Interest	0.05M	Perf Year	65.48%
Cash/sh	0.32	P/C	3.60	EPS next 5Y	-	ROE	-730.48%	52W Range	0.68 - 2.57	Perf YTD	-27.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-88.22%	ROI	-419.65%	52W High	-54.86%	Beta	-0.11
Dividend TTM	-	Quick Ratio	1.42	Sales past 5Y	5.96%	Gross Margin	-223.91%	52W Low	70.56%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	1.45	EPS Y/Y TTM	28.61%	Oper. Margin	-1862.69%	RSI (14)	28.67	Volatility	10.00% 9.30%
Employees	8	Debt/Eq	0.22	Sales Y/Y TTM	-21.76%	Profit Margin	-1863.36%	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	61.44%	Payout	-	Rel Volume	0.53	Prev Close	1.20
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	66.70%	Earnings	Mar 18 BMO	Avg Volume	108.09K	Price	1.16
SMA20	-14.61%	SMA50	-24.54%	SMA200	-21.35%	Trades		Volume	57,463	Change	-3.33%

Mar-19-24 06:53AM	CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-18-24 09:05AM	Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (Business Wire)
Mar-14-24 09:34AM	Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimers Disease (Business Wire)
Mar-13-24 05:04PM	Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Jan-29-24 09:15AM	Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimers Disease from the U.S. Patent and Trademark Office (Business Wire)
04:15PM	Loading…
Dec-27-23 04:15PM	Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. (Business Wire) -7.87%
Dec-18-23 09:15AM	Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol Cyclo Clinical Program for the Treatment of Niemann-Pick Disease Type C1 (Business Wire)
Dec-14-23 04:01PM	Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Nov-21-23 08:05AM	Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium 2024 (Business Wire) -8.82%
Nov-15-23 08:05AM	Cyclo Therapeutics Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 04:01PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results (GlobeNewswire) +8.63%
Oct-23-23 08:05AM	Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million (Business Wire) +7.33%
Oct-05-23 08:05AM	Cyclo Therapeutics to Present at 8th Annual Dawson James Conference (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -5.00%
08:05AM	Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement (Business Wire)
08:05AM	Loading…
Aug-15-23 08:05AM	Cyclo Therapeutics Reports Second Quarter 2023 Financial Results (Business Wire) -8.22%
Aug-02-23 08:16AM	Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc. (Business Wire)
Jun-29-23 01:32PM	Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C1 (Business Wire) -9.77%
Jun-13-23 04:01PM	Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire) +18.56%
Jun-12-23 08:05AM	Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo for Alzheimers Disease (Business Wire) +21.25%
Jun-05-23 08:05AM	Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement (Business Wire) +13.57%
May-15-23 08:05AM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (Business Wire) -12.39%
May-02-23 08:12AM	Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) (Business Wire) +15.97%
Apr-21-23 08:05AM	Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules (Business Wire) +7.53%
Mar-20-23 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results (Business Wire) -15.32%
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
08:05AM	Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements (Business Wire)
Jan-10-23 08:05AM	Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event (Business Wire)
Jan-09-23 08:05AM	Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo for the Treatment of Early Alzheimers Disease (Business Wire)
Jan-04-23 04:05PM	Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) +8.45%
08:05AM	Loading…
08:05AM	Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting (Business Wire)
Dec-30-22 08:00AM	Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
Nov-11-22 08:05AM	Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements (Business Wire)
Oct-18-22 08:05AM	Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C1 (NPC1) (Business Wire)
Oct-04-22 08:05AM	Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo for the Treatment of Early Alzheimers Disease (Business Wire) +7.92%
Sep-28-22 02:02PM	Cyclo Therapeutics Provides Business Update (Business Wire) +18.02%
Sep-07-22 08:05AM	Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (Business Wire) -7.71%
Aug-16-22 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-08-22 08:05AM	Cyclo Therapeutics to Present at the China NPC Association Meeting (Business Wire)
Jul-21-22 08:05AM	Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022 (Business Wire)
Jul-12-22 07:30AM	We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate (Simply Wall St.) -10.11%
Jul-11-22 08:05AM	Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022 (Business Wire) +7.39%
Jun-21-22 08:05AM	Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation (Business Wire)
May-18-22 08:00AM	Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
May-12-22 04:05PM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (Business Wire) +5.39%
May-09-22 08:05AM	Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event (Business Wire) -7.30%
Mar-29-22 08:35AM	Cyclo Therapeutics to Participate in the Virtual Investor Alzheimers Disease Spotlight Event (Business Wire)
Mar-24-22 08:05AM	Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo to Expand Pipeline (Business Wire)
Mar-23-22 08:25AM	Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (Business Wire)
Mar-14-22 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results (Business Wire) -11.75%
Mar-10-22 08:05AM	Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference (Business Wire)
Feb-08-22 08:05AM	Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo, at WORLDSymposium 2022 (Business Wire)
Feb-03-22 08:05AM	Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo in Niemann-Pick Disease Type C (Business Wire)
Jan-20-22 08:05AM	Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference (Business Wire)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Dec-16-21 06:16AM	Here's Why Cyclo Therapeutics (NASDAQ:CYTH) Must Use Its Cash Wisely (Simply Wall St.)
Dec-09-21 08:05AM	Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC Study Evaluating Trappsol® Cyclo for the Treatment of Niemann-Pick Disease (Business Wire)
Dec-06-21 08:05AM	Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo for the Treatment of Alzheimers Disease (Business Wire)
Nov-16-21 08:28PM	Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock (Business Wire)
04:27PM	Cyclo Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire)
08:05AM	Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo in Phase 2 Study for Treatment of Alzheimers Disease (Business Wire)
Nov-15-21 04:20PM	Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results (Business Wire)
Nov-10-21 08:05AM	Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event (Business Wire)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
Nov-02-21 08:05AM	Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimers Disease Asset (Business Wire) +9.45%
Oct-19-21 09:15AM	Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment (Business Wire)
Oct-18-21 08:05AM	Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) (Business Wire)
Oct-06-21 08:05AM	Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab (Business Wire)
Sep-27-21 08:05AM	Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer (Business Wire) +6.23%
Sep-15-21 08:05AM	Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (Business Wire)
Sep-08-21 08:05AM	Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-17-21 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results (Business Wire) +5.82%
Jul-30-21 08:05AM	Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C1 (Business Wire)
Jul-27-21 08:05AM	Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo (Business Wire)
Jun-21-21 08:05AM	Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation (Business Wire)
Jun-19-21 03:37AM	Here's Why Some Shareholders May Not Be Too Generous With Cyclo Therapeutics, Inc.'s (NASDAQ:CYTH) CEO Compensation This Year (Simply Wall St.)
Jun-17-21 08:05AM	Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo in Niemann-Pick Type C1 (Business Wire)
Jun-15-21 08:05AM	Cyclo Therapeutics Announces Launch of New Website (Business Wire) -5.18%
Jun-14-21 08:05AM	Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index (Business Wire)
Jun-12-21 04:06AM	Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely? (Simply Wall St.)
Jun-09-21 08:05AM	Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference (Business Wire)
May-20-21 09:05AM	Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimers Disease Panel (Business Wire) +5.79%
May-17-21 09:05AM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results (Business Wire)
May-11-21 09:05AM	Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy (Business Wire)
Apr-27-21 09:05AM	Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo in Niemann-Pick Type C1 (Business Wire)
Apr-20-21 09:25AM	Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo in Alzheimers Disease (Business Wire) +6.69%
Mar-25-21 08:35AM	Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo in Rare Disease Niemann-Pick Type C1 (NPC1) (Business Wire) -17.88%
Mar-15-21 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results (Business Wire)
Mar-12-21 08:05AM	Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference (Business Wire) +8.09%
Mar-10-21 08:35AM	Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer (Business Wire) -7.00%
Mar-09-21 09:05AM	Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo (Business Wire) +23.04%
Mar-04-21 09:10AM	Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C (Business Wire)
Mar-01-21 09:05AM	Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer (Business Wire)
Feb-22-21 09:00AM	Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families (Business Wire) -6.45%
Feb-09-21 08:05AM	Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo, at WORLDSymposium 2021 (Business Wire) +18.81%
Jan-26-21 08:00AM	Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo, at WORLDSymposium 2021 (Business Wire)
Jan-05-21 08:00AM	Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo in Patients with Niemann-Pick Disease Type C (Business Wire) +22.59%
Dec-22-20 02:30PM	Cyclo Therapeutics Announces Closing of Underwriters Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering (Business Wire) -9.55%
Dec-12-20 02:01AM	What Can We Learn About Cyclo Therapeutics' (NASDAQ:CYTH) CEO Compensation? (Simply Wall St.)

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rafael Holdings, Inc.	10% Owner	Aug 01 '23	Buy	1.25	4,000,000	5,000,000	6,514,970	Aug 02 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYTH

Cyclo Therapeutics Inc

Upgrade your FINVIZ experience